Innovent Announces First-Time Inclusion of SINTBILO® and New Indication for Olverembatinib in China's National Reimbursement Drug List

Core Viewpoint - Innovent Biologics has announced the inclusion of SINTBILO® and a new indication for olverembatinib in the updated 2024 National Reimbursement Drug List (NRDL), effective January 1, 2025, enhancing treatment options for patients in China [1][4]. Group 1: SINTBILO® (Tafolecimab Injection) - SINTBILO® is newly listed in the NRDL for treating adult patients with primary hypercholesterolemia and mixed dyslipidemia, marking Innovent's first entry into the cardiovascular field [2][6]. - The drug offers multiple dosing options: 150mg every two weeks, 450mg every four weeks, and 600mg every six weeks, significantly reducing low-density lipoprotein cholesterol (LDL-C) levels by nearly 70% and lipoprotein a (Lp(a)) by nearly 50% [2][5]. - As the first domestic PCSK9 inhibitor included in the NRDL, SINTBILO® provides a crucial new treatment option for cholesterol management in China [2][4]. Group 2: Olverembatinib - The updated NRDL includes a renewed indication for olverembatinib, which treats adult patients with chronic-phase chronic myeloid leukemia (CML-CP) or accelerated-phase CML (CML-AP) harboring the T315I mutation, and those resistant or intolerant to first- and second-generation tyrosine kinase inhibitors (TKIs) [3][8]. - Olverembatinib is recognized as the first third-generation BCR-ABL inhibitor approved by China's National Medical Products Administration (NMPA) [3][7]. - Innovent and Ascentage Pharma are committed to the commercialization of olverembatinib in the Chinese market [9]. Group 3: Company Mission and Future Outlook - The company aims to empower patients with affordable, high-quality biopharmaceuticals, focusing on oncology, cardiovascular and metabolic diseases, autoimmune conditions, and ophthalmology [4][10]. - Innovent has launched 11 products and has 5 new drug applications under regulatory review, with ongoing clinical trials for additional therapies [10]. - The company emphasizes a patient-centered approach to improve drug affordability and accessibility, contributing to better patient care [4][10].